BR112014024033A8 - Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes - Google Patents

Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes

Info

Publication number
BR112014024033A8
BR112014024033A8 BR112014024033A BR112014024033A BR112014024033A8 BR 112014024033 A8 BR112014024033 A8 BR 112014024033A8 BR 112014024033 A BR112014024033 A BR 112014024033A BR 112014024033 A BR112014024033 A BR 112014024033A BR 112014024033 A8 BR112014024033 A8 BR 112014024033A8
Authority
BR
Brazil
Prior art keywords
rosacea
treatment
sulpholipids
phospho
surfactants
Prior art date
Application number
BR112014024033A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014024033A2 (https=
Inventor
Mayo John
Henry William
Original Assignee
Sequessome Tech Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Tech Holdings Limited filed Critical Sequessome Tech Holdings Limited
Publication of BR112014024033A2 publication Critical patent/BR112014024033A2/pt
Publication of BR112014024033A8 publication Critical patent/BR112014024033A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fodder In General (AREA)
BR112014024033A 2012-03-29 2013-03-28 Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes BR112014024033A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
PCT/EP2013/056694 WO2013144289A1 (en) 2012-03-29 2013-03-28 Vesicular formulations

Publications (2)

Publication Number Publication Date
BR112014024033A2 BR112014024033A2 (https=) 2017-06-20
BR112014024033A8 true BR112014024033A8 (pt) 2017-07-25

Family

ID=46159988

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024033A BR112014024033A8 (pt) 2012-03-29 2013-03-28 Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes

Country Status (19)

Country Link
US (1) US9555051B2 (https=)
EP (1) EP2830630A1 (https=)
JP (1) JP2015511618A (https=)
KR (1) KR20150004798A (https=)
CN (1) CN104349782A (https=)
AU (1) AU2013241701A1 (https=)
BR (1) BR112014024033A8 (https=)
CA (1) CA2867749A1 (https=)
CL (1) CL2014002547A1 (https=)
CO (1) CO7121334A2 (https=)
EA (1) EA038899B1 (https=)
GB (2) GB201205642D0 (https=)
IL (1) IL234747A0 (https=)
IN (1) IN2014DN07913A (https=)
MX (1) MX2014011516A (https=)
NZ (1) NZ700472A (https=)
PH (1) PH12014502065A1 (https=)
SG (1) SG11201406144TA (https=)
WO (1) WO2013144289A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
CN107257681A (zh) * 2014-12-23 2017-10-17 卡姆拉斯公司 控释配制品
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US20240299378A1 (en) * 2021-02-25 2024-09-12 Exinov Emulsion for use in the treatment of rosacea

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
JPS63501289A (ja) 1985-09-27 1988-05-19 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア リポソ−ム経皮薬剤供給系
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003122A1 (de) 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
CA2139757C (en) 1992-07-08 2009-04-14 Gunther Maierhofer Liposomes, method of preparing the same and use thereof in the preparation of drugs
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
US6534070B1 (en) * 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
BR9816014A (pt) 1998-09-01 2001-05-08 Idea Ag Transporte eletricamente controlado de penetrantes carregados através de barreiras
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
DE60122304T2 (de) 2000-04-12 2007-08-09 Liplasome Pharma A/S Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
PL367337A1 (pl) 2001-05-31 2005-02-21 Pharmacia Corporation Przenikająca przez skórę kompozycja selektywnego inhibitora cyklooksygenazy-2
US20050123593A1 (en) 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
AU2003233396B2 (en) 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CN1703199B (zh) 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
JP2006525368A (ja) 2003-05-02 2006-11-09 アロネックス，ファーマシューティカルズ，インコーポレーテッド 脂質白金錯体およびその使用方法
EA200600297A1 (ru) 2003-07-21 2006-08-25 Васоджен Айеленд Лимитед Лечение острого воспалительного состояния
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
UA89545C2 (uk) 2005-08-29 2010-02-10 Сепсикюр Л.Л.К. Спосіб лікування чи попередження станів, викликаних грампозитивними бактеріями
NZ569068A (en) 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
CA2664944C (en) 2006-09-28 2016-06-14 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
JP4732307B2 (ja) * 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
KR20110128283A (ko) 2009-02-05 2011-11-29 타겟티드 딜리버리 테크놀러지스 리미티드 미생물체의 증식 및 생존도를 감소시키는 방법
CN105434353A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
AU2014298426B2 (en) 2013-07-31 2019-07-18 Sequessome Technology Holdings Limited Vesicles

Also Published As

Publication number Publication date
CN104349782A (zh) 2015-02-11
GB2515440B (en) 2017-02-08
BR112014024033A2 (https=) 2017-06-20
CO7121334A2 (es) 2014-11-20
JP2015511618A (ja) 2015-04-20
GB201205642D0 (en) 2012-05-16
SG11201406144TA (en) 2014-10-30
CA2867749A1 (en) 2013-10-03
CL2014002547A1 (es) 2015-03-27
MX2014011516A (es) 2015-04-08
GB2515440A (en) 2014-12-24
IN2014DN07913A (https=) 2015-04-24
PH12014502065A1 (en) 2014-12-10
EP2830630A1 (en) 2015-02-04
US20150057249A1 (en) 2015-02-26
EA038899B1 (ru) 2021-11-03
AU2013241701A1 (en) 2014-10-16
IL234747A0 (en) 2014-11-30
US9555051B2 (en) 2017-01-31
KR20150004798A (ko) 2015-01-13
NZ700472A (en) 2016-02-26
GB201419075D0 (en) 2014-12-10
WO2013144289A1 (en) 2013-10-03
EA201491581A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
JOP20170135A1 (ar) مركبات ديازاسبيروألكيل مثيل-إندول
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112017027721A2 (pt) formulação de alta concentração
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
DOP2016000253A (es) Nuevos compuestos
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]